PureTech Health (LON:PRTC) Shares Cross Below Fifty Day Moving Average - Here's Why

Key Points

• Technical signal: Shares crossed below their 50-day moving average (50-day MA GBX 125.47), trading as low as GBX 108 on volume of 774,681 shares.
• Analyst view: Peel Hunt reiterated a Buy rating with a GBX 508 price target, and the consensus rating on MarketBeat is also Buy with an average target of GBX 508.
• Key fundamentals: The company shows strong liquidity (current ratio 8.49, quick ratio 2.51), a low trailing P/E of 6.35, a market cap of £261.02 million, and a debt-to-equity ratio of 5.56.

Shares of PureTech Health plc (LON:PRTC - Get Free Report) crossed below its 50-day moving average during trading on Monday . The stock has a 50-day moving average of GBX 125.47 and traded as low as GBX 108. PureTech Health shares last traded at GBX 108, with a volume of 774,681 shares.

Wall Street Analysts Forecast Growth

Separately, Peel Hunt restated a "buy" rating and issued a GBX 508 price target on shares of PureTech Health in a report on Monday, December 8th. One equities research analyst has rated the stock with a Buy rating, Based on data from MarketBeat, PureTech Health has an average rating of "Buy" and a consensus price target of GBX 508.

PureTech Health Price Performance

The company has a current ratio of 8.49, a quick ratio of 2.51 and a debt-to-equity ratio of 5.56. The company has a market capitalization of £261.02 million, a P/E ratio of 6.35 and a beta of 0.69. The firm's 50 day moving average price is GBX 125.47 and its two-hundred day moving average price is GBX 126.51.

About PureTech Health

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule. It is also developing technology and products for screening, diagnosis, and treatment of neurological disorders, such as ADHD, autism, and depression through computer software; noninvasive neurostimulation treatment for psychiatric disorders; and combination therapy for schizophrenia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.